PMID- 12787539
OWN - NLM
STAT- MEDLINE
DCOM- 20030827
LR  - 20191107
IS  - 1521-6934 (Print)
IS  - 1521-6934 (Linking)
VI  - 17
IP  - 3
DP  - 2003 Jun
TI  - Inherited thrombophilias and anticoagulation in pregnancy.
PG  - 471-89
AB  - Thromboprophylaxis, primary or secondary, should be considered in selected 
      pregnant women with inherited thrombophilias; such women may be divided into 
      high-, medium- and low-risk categories on the basis of the specific thrombophilic 
      defect and any personal or family history of venous thromboembolism (VTE). Women 
      at high risk of VTE should receive treatment doses of low-molecular-weight 
      heparin (LMWH) throughout pregnancy and should remain on anticoagulation for 6 
      weeks postpartum, or, where appropriate, long-term. Women at moderate risk should 
      be treated with prophylactic fixed-dose LMWH throughout pregnancy and for 6 weeks 
      postpartum. Women at low risk should receive prophylactic fixed-dose LMWH for 6 
      weeks postpartum, and low-dose aspirin LDA should be considered during pregnancy. 
      LWMH offers important advantages over unfractionated heparin (UFH); 
      heparin-induced thrombocytopaenia (HIT) and osteopaenia are rarely seen. For 
      treatment doses of LMWH, dosage adjustment based on anti-Xa levels is usually 
      required as pregnancy progresses. Warfarin should be avoided throughout 
      pregnancy. LMWH, UFH and warfarin are safe for breast-feeding mothers.
FAU - Bowles, Louise
AU  - Bowles L
AD  - Department of Haematology, University College London Hospitals, WC1E 6DB, London, 
      UK.
FAU - Cohen, Hannah
AU  - Cohen H
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Best Pract Res Clin Obstet Gynaecol
JT  - Best practice & research. Clinical obstetrics & gynaecology
JID - 101121582
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Female
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/*drug therapy
MH  - Prenatal Care/methods
MH  - Thrombophilia/*drug therapy/genetics
MH  - Venous Thrombosis/prevention & control
RF  - 80
EDAT- 2003/06/06 05:00
MHDA- 2003/08/28 05:00
CRDT- 2003/06/06 05:00
PHST- 2003/06/06 05:00 [pubmed]
PHST- 2003/08/28 05:00 [medline]
PHST- 2003/06/06 05:00 [entrez]
AID - S1521693403000129 [pii]
AID - 10.1016/s1521-6934(03)00012-9 [doi]
PST - ppublish
SO  - Best Pract Res Clin Obstet Gynaecol. 2003 Jun;17(3):471-89. doi: 
      10.1016/s1521-6934(03)00012-9.